Bowel Cancer Stool Test (FIT) May Need Age-Specific Thresholds for Under-50s

A stool test widely used to detect bowel cancer may need different threshold values for patients under 50, an international review led by the University of Nottingham published in the journal Gut suggests.

Among more than 69,000 symptomatic younger patients, only about 1 in 300 turn out to have the disease.

The test in question is the faecal immunochemical test, or FIT, which general practitioners use to detect microscopic traces of blood in the stool of people with symptoms that could indicate bowel cancer.

A negative result means the risk is very low and no further tests are needed. A result of ten or above triggers an urgent referral to hospital for a colonoscopy, a camera examination that is invasive and can be uncomfortable.

The review, led by Professor David Humes of the University of Nottingham School of Medicine and the NIHR Nottingham Biomedical Research Centre, pooled twelve studies covering more than 69,000 people under 50 who had symptoms and had undergone FIT. It compared their outcomes with those of patients over 50, in whom the risk of bowel cancer was three to seven times higher.

Bowel cancer is the fourth most common cancer and the second highest cause of cancer death in the UK, according to Cancer Research UK, and diagnoses before the age of 50 — so-called early-onset bowel cancer — are rising worldwide. That makes the finding consequential: the same cut-off of ten is being applied across all ages, yet it may not perform equally well for everyone.

Bowel Cancer Stool Test (FIT) May Need Age-Specific Thresholds for Under-50s
Photo: scienmag.com

Negative FIT still signals very low cancer risk in younger people

  • FIT works: a negative result in a younger person with symptoms still means bowel cancer risk is very low.
  • A score of ten or above sends patients for urgent colonoscopy — but this threshold was built largely on data from people over 50.
  • Because younger patients have lower baseline risk, far more of them would need colonoscopies to find one cancer; researchers say the cut-off needs age-specific adjustment.

One in 300 younger patients had cancer

The numbers behind the concern are stark. Among symptomatic people under 50 who took a FIT, only about 0.35 per cent — one in 300 — were ultimately diagnosed with bowel cancer, the research team found. In people over 50, that risk was three to seven times higher.

The consequence is a numbers problem for hospitals. Because the starting risk is so much lower in younger groups, many more people under 50 would have to undergo the invasive camera test to find a single case of bowel cancer compared with older adults, the study authors reported.

Bowel Cancer Stool Test (FIT) May Need Age-Specific Thresholds for Under-50s
Photo: miragenews.com
Measure Under 50 with symptoms Over 50 with symptoms
Current referral cut-off (FIT score) 10 or above 10 or above
Studies pooled in review 12 studies, more than 69,000 people under 50

Why one threshold may not fit every age

The researchers stress that FIT remains a good test for diagnosing bowel cancer. The problem is not the test itself but the fixed cut-off of ten, which was established when most evidence came from patients over 50 — a group whose baseline cancer risk differs sharply from younger people’s.

“For the first time, our international research brings together the current evidence base for using stool tests in the diagnosis of patients with symptoms of suspected colorectal cancer with a particular focus on how the test performs by age. Further work is now needed to assess the optimum FIT cut-off or integration of FIT into individualised CRC risk prediction models in patients under 50 years and to examine alternative causes of a raised FIT in younger age groups,” said Professor David Humes, senior author of the research.

Scienmag’s report adds a further nuance the underlying paper raises: raised FIT results in younger patients may have alternative, non-cancerous causes, and the review’s authors say those still need to be examined. That question — what else causes a positive result in someone under 50 — remains open.

Early-onset cancer drives the urgency

The push to refine diagnosis in younger people comes against a global backdrop of rising early-onset colorectal cancer, meaning diagnoses before age 50, which the study’s collaborators highlight as a growing public health concern. Healthcare systems worldwide, including the NHS in the UK — where FIT is embedded in GP referral pathways — now face the task of separating genuine risk from over-investigation in this younger group.

“Early-onset colorectal cancer is rising worldwide, and this is exactly the kind of question our Global Research Collaborative was built to answer. By pooling evidence across countries, this team has shown that one FIT threshold may not work equally well for every age group,” said Anjee Davis, MPPA, Chief Executive Officer of the US-based charity Fight Colorectal Cancer, which supported the research alongside COLOREACH-UK. Chief Executive Officer

Medicalxpress framed the review’s headline finding as a challenge to a “one-size-fits-all” cut-off, while Scienmag emphasised its practical cost: unnecessary invasive procedures for younger patients. The sources do not disagree on the data — only on which framing to lead with.

What researchers still need to answer

The authors, writing in Gut on November 18 in a systematic review led by Moksh Sharma of Nottingham University Hospitals NHS Trust and the University of Nottingham, with collaborators including the University of Glasgow, are explicit about what remains unresolved. The optimum FIT cut-off for patients under 50 has not been determined, and neither has the best way to integrate FIT into individualised colorectal cancer risk prediction models for that age group.

In other words, no new threshold is being recommended today. The review establishes the evidence base and the size of the problem — 69,000 patients showing how unevenly one number performs across ages — and leaves the recalibration to future research, which the team says is required so that the right patients can be prioritised and diagnosis accelerated.

Current clinical guidance unchanged after review findings

FIT is a diagnostic triage tool, not a rule-out on its own for every situation. The sources do not report any change to current clinical guidance: under existing protocols, a negative FIT still indicates very low bowel cancer risk, while a result of ten or above warrants urgent hospital referral for colonoscopy.

Anyone with bowel cancer symptoms — the review population included people whose symptoms could be caused by the disease — should consult a GP regardless of age, and any change to referral thresholds would come from clinical bodies and regulators, not from this single review.

Where this leads next

The next steps the researchers name are concrete: assessing the optimum FIT cut-off for under-50s, testing age-aware risk prediction models, and investigating alternative causes of raised FIT results in younger patients. Whether regulators and clinical guideline bodies — from NHS England to equivalents elsewhere — eventually adopt age-adjusted thresholds is the open question this evidence now puts on the table.

References

  • Sharma, M., et al. (2026). How well does the faecal immunochemical test (FIT) detect colorectal cancer in primary care patients under 50 with symptoms: a systematic review. Gut. https://gut.bmj.com/content/early/2026/11/15/gutjnl-2026-339890
  • News-Medical: Common bowel cancer test needs age adjustments for younger people.
  • Medicalxpress: Study of more than 69,000 younger patients casts doubt on a universal cutoff for the colorectal cancer stool test.
  • Scienmag: Bowel Cancer Stool Tests May Require Tailored Cut-Offs for Younger Patients.
  • Mirage.News: Research Reveals How Bowel Cancer Test Performs in Younger People.
Photo of author

Health Desk

Health Desk at Archyde.

New Mexico Film Office: Pluribus Season 2 to Film in State, 500+ Crew